Rhumbline Advisers bought a new stake in Constellation Pharmaceuticals Inc (NASDAQ:CNST) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 16,312 shares of the company’s stock, valued at approximately $221,000.
Other institutional investors have also added to or reduced their stakes in the company. BNP Paribas Arbitrage SA increased its position in shares of Constellation Pharmaceuticals by 4,092.4% in the first quarter. BNP Paribas Arbitrage SA now owns 3,312 shares of the company’s stock valued at $45,000 after buying an additional 3,233 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Constellation Pharmaceuticals by 16.9% in the fourth quarter. Geode Capital Management LLC now owns 13,735 shares of the company’s stock valued at $55,000 after buying an additional 1,987 shares in the last quarter. Northern Trust Corp increased its position in shares of Constellation Pharmaceuticals by 12.4% in the fourth quarter. Northern Trust Corp now owns 51,008 shares of the company’s stock valued at $204,000 after buying an additional 5,624 shares in the last quarter. Sphera Funds Management LTD. purchased a new position in shares of Constellation Pharmaceuticals in the fourth quarter valued at $281,000. Finally, Vanguard Group Inc. purchased a new position in shares of Constellation Pharmaceuticals in the third quarter valued at $989,000. 64.38% of the stock is owned by institutional investors.
A number of research analysts have recently weighed in on CNST shares. Zacks Investment Research cut Constellation Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, March 5th. Oppenheimer raised their price target on Constellation Pharmaceuticals from $14.00 to $18.00 and gave the company an “outperform” rating in a research report on Tuesday, April 2nd. Finally, HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of Constellation Pharmaceuticals in a research report on Wednesday, June 5th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $16.82.
Shares of CNST stock opened at $9.32 on Friday. Constellation Pharmaceuticals Inc has a fifty-two week low of $4.01 and a fifty-two week high of $14.04. The company has a debt-to-equity ratio of 0.25, a current ratio of 6.92 and a quick ratio of 6.92.
Constellation Pharmaceuticals (NASDAQ:CNST) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.75) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.05. As a group, equities research analysts anticipate that Constellation Pharmaceuticals Inc will post -3.13 EPS for the current year.
Constellation Pharmaceuticals Profile
Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors.
Featured Story: Are 12b-1 Fees Affecting Your Mutual Fund Performance?
Want to see what other hedge funds are holding CNST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Constellation Pharmaceuticals Inc (NASDAQ:CNST).
Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.